Literature DB >> 12667414

Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored.

Jan Buter1, Herbert M Pinedo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12667414     DOI： 10.1007/s11912-003-0106-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  76 in total

1.  Natural adjuvants: endogenous activators of dendritic cells.

Authors:  S Gallucci; M Lolkema; P Matzinger
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

2.  Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.

Authors:  S Kasimir-Bauer; S Mayer; P Bojko; D Borquez; R Neumann; S Seeber
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

3.  Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth.

Authors:  G A Homandberg; J E Williams; D Grant; B Schumacher; R Eisenstein
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

4.  Doxorubicin gradients in human breast cancer.

Authors:  J Lankelma; H Dekker; F R Luque; S Luykx; K Hoekman; P van der Valk; P J van Diest; H M Pinedo
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

5.  Immune surveillance against a solid tumor fails because of immunological ignorance.

Authors:  A F Ochsenbein; P Klenerman; U Karrer; B Ludewig; M Pericin; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 6.  Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

Authors:  J Schlom; J Kantor; S Abrams; K Y Tsang; D Panicali; J M Hamilton
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

7.  Tumor induction of VEGF promoter activity in stromal cells.

Authors:  D Fukumura; R Xavier; T Sugiura; Y Chen; E C Park; N Lu; M Selig; G Nielsen; T Taksir; R K Jain; B Seed
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer.

Authors:  K Hoekman; J Wagstaff; C J van Groeningen; J B Vermorken; E Boven; H M Pinedo
Journal:  J Natl Cancer Inst       Date:  1991-11-06       Impact factor: 13.506

10.  The induction of tolerance by dendritic cells that have captured apoptotic cells.

Authors:  R M Steinman; S Turley; I Mellman; K Inaba
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307
View more
  2 in total

1.  A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.

Authors:  Kathleen M Schmeler; Saroj Vadhan-Raj; Pedro T Ramirez; Sachin M Apte; Lorenzo Cohen; Roland L Bassett; Revathy B Iyer; Judith K Wolf; Charles L Levenback; David M Gershenson; Ralph S Freedman
Journal:  Gynecol Oncol       Date:  2009-03-04       Impact factor: 5.482

2.  Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin.

Authors:  Sachin M Apte; Saroj Vadhan-Raj; Lorenzo Cohen; Roland L Bassett; Ilyssa O Gordon; Charles F Levenback; Pedro T Ramirez; Stacie T Gallardo; Rebecca S Patenia; Michael E Garcia; Revathy B Iyer; Ralph S Freedman
Journal:  J Transl Med       Date:  2006-04-07       Impact factor: 5.531
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.